Virax Biolabs Group Limited Ordinary Shares
Here’s whether Virax Biolabs Group Limited Ordinary Shares (VRAX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 48 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-11.83% over 10 days); weak 1-year return of -85.5%; 3-month momentum negative (-51.0%); rising volume on a downtrend (distribution, 2.02x avg). Currently 87.5% off its 52-week high. Score: -5/7.
VRAX is trading below its 200-day MA ($0.49) — a key warning sign the longer-term trend is under pressure. An RSI of 48.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -85.5% compares to +35.1% for SPY (trailed the market by 120.5%). The current 87.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.